Compositions and methods for the treatment of neuromyelitis optica

Patent metadata

Field	Value
Publication number	US-10654916-B2
Application number	US-201214113061-A
Country	US
Kind code	B2
Filing date	Apr 23, 2012
Priority date	Apr 21, 2011
Publication date	May 19, 2020
Grant date	May 19, 2020

Abstract

The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.

First claim

What is claimed is:

1. A method of treating a subject with neuromyelitis optica (NMO) spectrum disease comprising administering to said subject a reagent comprising an anti-aquaporin-4 (AQP4) antibody or an antigen binding fragment thereof, wherein said AQP4 antibody or an antigen binding fragment thereof comprises a mutated Fc region of IgG1 antibody which lacks effector functions of an intact antibody, wherein the effector functions are activation of complement and recruitment of immune cells, and
wherein said AQP4 antibody or an antigen binding fragment thereof comprises
i) a light chain variable region comprising SEQ ID NO: 6, and a heavy chain variable region comprising SEQ ID NO: 8;
ii) a light chain variable region comprising SEQ ID NO: 10, and a heavy chain variable region comprising SEQ ID NO: 12; or
iii) a light chain variable region comprising SEQ ID NO: 19, and a heavy chain variable region comprising SEQ ID NO: 17.

2. The method of claim 1 , wherein
i) said light chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 5, and said heavy variable chain region is encoded by the nucleotide sequence comprising SEQ ID NO: 7;
ii) said light chain variable region encoded by the nucleotide sequence comprising SEQ ID NO: 9, and said heavy chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 11; or
iii) said light chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 20, and said heavy chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 18.

3. The method of claim 1 , wherein said subject is a human subject.

4. The method of claim 1 , wherein administering comprises intraocular, intraatertial, subcutaneous, intravenous administration or intrathecal route of administration.

5. The method of claim 1 , wherein said mutated Fc region comprises an IgG1 sequence having L234A/L235A substitutions.

6. The method of claim 1 , wherein said mutated Fc region comprises an IgG1 sequence having a K322A substitution.

7. The method of claim 1 , wherein said mutated Fc region comprises an IgG1 sequence having a G237A amino acid substitution.

8. The method of claim 1 , wherein said mutated Fc region comprises an IgG1 sequence having L234A/L235A/G237A substitutions.

9. The method of claim 1 , wherein said mutated Fc region comprises a chemically modified Fc region, an antibody Fab fragment and lacks an Fc region, an antibody Fab fragment fused to a non-antibody protein segment, or a single chain antibody or F(ab) 2 .

10. The method of claim 1 , wherein treating comprises reducing one or more of retinal ganglion cell death, optic nerve injury, spinal cord injury, axonal transection, optic nerve demyelination, spinal cord demyelination, astrocyte death or oligodendrocyte death.

11. The method of claim 1 , wherein said reagent is administered upon onset of or following an NMO attack.

12. The method of claim 11 , wherein said reagent is administered within about 1 hour, 6 hours, 12 hours, 24 hours or two days of an NMO attack.

13. The method of claim 1 , further comprising administering to said subject a second agent that treats one or more aspect of NMO.

14. The method of claim 1 , further comprising assessing said patient for positive NMO-IgG (AQP4) serology.

15. The method of claim 1 , wherein said subject exhibits positive NMO-IgG (AQP4) serology.

16. The method of claim 1 , wherein said subject exhibits one or more of transverse myelitis, optic neuritis or other unrelated neurologic dysfunction.

17. The method of claim 16 , wherein unrelated neurologic dysfunction comprises protracted nausea or vomiting.

18. A method to reduce exacerbations of neuromyelitis optica (NMO) spectrum disease in a subject comprising administering to said subject a reagent comprising an anti-aquaporin-4 (AQP4) antibody or an antigen binding fragment thereof, wherein said AQP4 antibody or an antigen binding fragment thereof comprises a mutated Fc region of IgG1 antibody which lacks effector functions of an intact antibody, wherein the effector functions are activation of complement and recruitment of immune cells, and
wherein said AQP4 antibody or an antigen binding fragment thereof comprises
i) a light chain variable region comprising SEQ ID NO: 6, and a heavy chain variable region comprising SEQ ID NO: 8;
ii) a light chain variable region comprising SEQ ID NO: 10, and a heavy chain variable region comprising SEQ ID NO: 12; or
iii) a light chain variable region comprising SEQ ID NO: 19, and a heavy chain variable region comprising SEQ ID NO: 17.

19. The method of claim 18 , wherein
i) said light chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 5, and said heavy variable chain region is encoded by the nucleotide sequence comprising SEQ ID NO: 7;
ii) said light chain variable region encoded by the nucleotide sequence comprising SEQ ID NO: 9, and said heavy chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 11; or
iii) said light chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 20, and said heavy chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 18.

20. A method of reducing the progression of neuromyelitis optica (NMO) spectrum disease in a subject comprising administering to said subject a reagent comprising an anti-aquaporin-4 (AQP4) antibody or an antigen binding fragment thereof, wherein said AQP4 antibody or an antigen binding fragment thereof comprises a mutated Fc region of IgG1 antibody which lacks effector functions of an intact antibody, wherein the effector functions are activation of complement and recruitment of immune cells, and
wherein said AQP4 antibody or an antigen binding fragment thereof comprises
i) a light chain variable region comprising SEQ ID NO: 6, and a heavy chain variable region comprising SEQ ID NO: 8;
ii) a light chain variable region comprising SEQ ID NO: 10, and a heavy chain variable region comprising SEQ ID NO: 12; or
iii) a light chain variable region comprising SEQ ID NO: 19, and a heavy chain variable region comprising SEQ ID NO: 17.

21. The method of claim 20 , wherein
i) said light chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 5, and said heavy variable chain region is encoded by the nucleotide sequence comprising SEQ ID NO: 7;
ii) said light chain variable region encoded by the nucleotide sequence comprising SEQ ID NO: 9, and said heavy chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 11; or
iii) said light chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 20, and said heavy chain variable region is encoded by the nucleotide sequence comprising SEQ ID NO: 18.

22. A reagent comprising an anti-aquaporin-4 (AQP4) antibody or an antigen binding fragment thereof, wherein said AQP4 antibody or an antigen binding fragment thereof comprises a mutated Fc region of IgG1 antibody which lacks effector functions of an intact antibody, wherein the effector functions are activation of complement and recruitment of immune cells, and
wherein said AQP4 antibody or an antigen binding fragment thereof comprises
i) a light chain variable region comprising SEQ ID NO: 6, and a heavy chain variable region comprising SEQ ID NO: 8;
ii) a light chain variable region comprising SEQ ID NO: 10, and a heavy chain variable region comprising SEQ ID NO:

Assignees

• Bennett Jeffrey L
• Owens Gregory P
• Verkman Alan S
• The Regents Of The Univ Of California A California Corporation
• Univ Colorado Regents

Inventors

• Bennett Jeffrey L
• Owens Gregory P
• Verkman Alan S

Classifications

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title